On April 27, 2017 Ipsen, a global specialty-driven pharmaceutical group, reported sales for the first quarter of 2017 (Press release, Ipsen, APR 27, 2017, View Source [SID1234518698]). Schedule your 30 min Free 1stOncology Demo! 2017 first quarter sales
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the first quarter of 2017, Consolidated Group sales grew 19.1% to €438.0 million driven by Specialty Care growth of 25.4%1 including growth of 86.3%1 from North America.
Commenting on the first quarter 2017 performance, David Meek, Chief Executive Officer of Ipsen said: "In the first quarter, Specialty Care continued to drive remarkable organic top-line growth for Ipsen, led by the outstanding performance of Somatuline, both in the United States and Europe, as well as a strong acceleration for Dysport. We continue to face headwinds in certain emerging markets for our Consumer Healthcare business." David Meek continued, "After the successful closing of the Onivyde transaction, our largest acquisition to date, we are focused on the successful execution of the Onivyde and Cabometyx launches. These two important products strengthen our presence in Oncology and will contribute meaningfully to our top-line growth and profitability in the coming years."
Ipsen confirms its financial targets for 2017, with Specialty Care sales growth year-on-year greater than +18.0%1, Consumer Healthcare sales growth year-on-year greater than +4.0%1 and Core Operating margin greater than 24% of net sales.
In addition, Ipsen announces the change in name of its Primary Care division to Consumer Healthcare. This reflects the evolution over the last two years of the promotional model from classical prescription-based to a combination of prescription and over-the-counter (OTx) in select countries with gastrointestinal portfolios. The transaction announced in February to acquire a portfolio of select consumer healthcare assets from Sanofi will strengthen the evolution of the Consumer Healthcare portfolio in France and Central Europe with the strategic intent to further develop the OTx model in most geographies.
View Ipsen’s full Q1 report at View Source